This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Page standards status: Informative |
Generated Narrative: ArtifactAssessment 179693
version: 7; Last updated: 2024-12-12 13:06:16+0000
Profile: CertaintyOfEvidence
Artifact URL: https://fevir.net/resources/ArtifactAssessment/179693
Artifact Description:
This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.
identifier: FEvIR Object Identifier/https://fevir.net/FOI/179693
title: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
artifact: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
content
summary:
Low certainty due to inconsistency and risk of bias
type: Overall certainty
classifier: Low quality
component
type: Publication bias
classifier: no serious concern
component
summary:
There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.
type: Inconsistency
classifier: serious concern
component
summary:
Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.
type: Imprecision
classifier: no serious concern
component
type: Indirectness
classifier: no serious concern
component
type: Risk of bias
classifier: serious concern
Components
Summary Type Classifier No blinding (no placebo control) in the largest trial
Lack of blinding present